BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28614980)

  • 1. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
    Bond TC; Szabo E; Gabriel S; Klastersky J; Tomey O; Mueller U; Schwartzberg L; Tang B
    J Oncol Pharm Pract; 2018 Sep; 24(6):412-423. PubMed ID: 28614980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H; Illerhaus G; Martens UM; Salar A; Depenbusch R; Köhler A; Engelhardt M; Mahlmann S; Zaiss M; Lammerich A; Bias P; Buchner A
    Support Care Cancer; 2021 May; 29(5):2519-2527. PubMed ID: 32944800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
    Wang L; Baser O; Kutikova L; Page JH; Barron R
    Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
    BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
    Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
    Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM; Bias P; Buchner A
    Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
    Donkor KN; Selim JH; Waworuntu A; Lewis K
    Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany.
    Link H; Thompson SF; Tian M; Haas JS; Meise D; Maas C; Dimitrov S
    Support Care Cancer; 2022 Nov; 30(11):9317-9327. PubMed ID: 36076105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
    Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
    Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
    Crawford J
    Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
    Botteri E; Krendyukov A; Curigliano G
    Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim.
    Curran MP; Goa KL
    Drugs; 2002; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
    Molineux G
    Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
    Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
    Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Gao L; Li SC
    Breast Cancer; 2018 Nov; 25(6):671-680. PubMed ID: 29802592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
    Guariglia R; Martorelli MC; Lerose R; Telesca D; Milella MR; Musto P
    Biologics; 2016; 10():1-8. PubMed ID: 26858523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T; Densmore JJ
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.